Cargando…
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
BACKGROUND: CALM was a randomized phase 3 trial in patients with Crohn’s disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs...
Autores principales: | Reinisch, Walter, Panaccione, Remo, Bossuyt, Peter, Baert, Filip, Armuzzi, Alessandro, Hébuterne, Xavier, Travis, Simon, Danese, Silvio, Sandborn, William J, Schreiber, Stefan, Berg, Sofie, Zhou, Qian, Kligys, Kristina, Neimark, Ezequiel, Suleiman, Ahmed A, D’Haens, Geert, Colombel, Jean-Frederic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500520/ https://www.ncbi.nlm.nih.gov/pubmed/32105310 http://dx.doi.org/10.1093/ibd/izaa025 |
Ejemplares similares
-
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020) -
A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY
por: Panaccione, R, et al.
Publicado: (2022) -
The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017) -
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018) -
Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)